The WHO has recommended widespread use of the world’s first malaria vaccine ‘Mosquirix’ among children in sub-Saharan Africa and other regions.
The decision came after pilots held in three countries since 2019 found that it reduced cases by 40%. WHO chief Tedros Adhanom Ghebreyesus described the vaccine as a “breakthrough for science” as malaria kills over 4,00,000 in a year.
The vaccine developed by GlaxoSmithKline Plc and its partners won a recommendation from the World Health Organization (WHO for use in children in sub-Saharan Africa and other regions with moderate to high transmission. It marks a turning point in a battle against the parasite that causes malaria.
